GENECAST is a company specialized in ctDNA liquid biopsy.
Our outstanding detection sensitivity
Improves cancer management systems,
Provides more cancer treatment options,
Results in a higher success rate of targeted therapy development.
This ultimately means that earlier cancer diagnosis will be possible and explains
why GENECAST is dedicated to improving the detection sensitivity of liquid biopsy.
Our technology takes you one step closer to accurately analyzing the origins of cancer.
GENECAST’s ADPS™ selectively amplifies mutant genes only while leaving wild-type intact.
Analyzing EGFR mutations, the most common mutations in non-small cell lung cancer (NSCLC) with up to 0.01% detection sensitivity.
GENECAST’s ADPS™ lets you directly face the causes of cancer by providing
a precise analysis of circulating tumor DNA (ctDNA) within us.
It recommends a more extensive range of appropriate treatment options to
clinicians and ultimately helps make cancer a manageable disease by providing
an accurate diagnosis, prognosis, prescription and recurrence monitoring as well as precision medicine.
GENECAST supports you in the fight against cancer.